Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Long-Term Deferred Tax (2016 - 2025)

Sanofi (SNY) has disclosed Long-Term Deferred Tax for 11 consecutive years, with $10.0 billion as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 17.7% to $10.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 billion through Dec 2025, up 17.7% year-over-year, with the annual reading at $9.7 billion for FY2025, 12.78% up from the prior year.
  • Long-Term Deferred Tax hit $10.0 billion in Q4 2025 for Sanofi, up from $8.5 billion in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $10.0 billion in Q4 2025 to a low of $5.3 billion in Q4 2021.
  • Historically, Long-Term Deferred Tax has averaged $7.2 billion across 5 years, with a median of $6.9 billion in 2023.
  • Biggest five-year swings in Long-Term Deferred Tax: grew 4.37% in 2022 and later rose 25.96% in 2023.
  • Year by year, Long-Term Deferred Tax stood at $5.3 billion in 2021, then rose by 4.37% to $5.5 billion in 2022, then increased by 25.96% to $6.9 billion in 2023, then rose by 23.12% to $8.5 billion in 2024, then grew by 17.7% to $10.0 billion in 2025.
  • Business Quant data shows Long-Term Deferred Tax for SNY at $10.0 billion in Q4 2025, $8.5 billion in Q4 2024, and $6.9 billion in Q4 2023.